KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual Commitments And ObligationsCost Of SalesDevelopment ExpensesEffective Tax Rate %Employees By RegionGross Margin %Gross ProfitIncome Before Income Taxes By RegionInventory BreakdownLong Lived Assets By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX BreakdownProduct Revenue By RegionProduct Revenue By Region %Product Revenue By Region AnnualProduct Revenue By Region Annual %Property And Equipment BreakdownResearch Expenses BreakdownRevenue By Business VerticalRevenue By Business Vertical (Annual)Revenue By Business Vertical AnnualRevenue By Customer (Annual) %Revenue By Location Of Customer (Product)Revenue By Location Of Customer (Product) %Revenue By Location Of Customer (Product Annual)Revenue By Product CategoryRevenue By Product Category %Revenue By Product Category (Annual)Revenue Mix By Business Vertical Annual %Revenue Mix By Product Category (Annual) %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Gross Profit (2010 - 2026)

Vertex Pharmaceuticals' quarterly Gross Profit came in at $2.6 billion in Q1 2026, up 7.76% year-on-year from $2.4 billion in Q1 2025, and down 4.77% quarter-over-quarter from $2.7 billion in Q4 2025.

Vertex Pharmaceuticals has reported Gross Profit for 17 years, with the latest figure at $2.6 billion in Q1 2026.

  • For the quarter ending Q1 2026, Gross Profit rose 7.76% year-over-year to $2.6 billion; the trailing twelve-month figure through Mar 2026 stood at $10.5 billion (up 10.35% YoY), and the FY2025 full-year result was $10.4 billion, up 9.07% from the prior year.
  • Gross Profit for Q1 2026 stood at $2.6 billion, down from $2.7 billion in the prior quarter.
  • The five-year high for Gross Profit was $2.7 billion in Q4 2025, with the low at $1.9 billion in Q1 2022.
  • Average Gross Profit over 5 years is $2.3 billion, with a median of $2.3 billion recorded in 2024.
  • Year-over-year, Gross Profit climbed 23.57% in 2022 and gained 2.52% in 2025.
  • Tracing VRTX's Gross Profit over 5 years: stood at $2.0 billion in 2022, then advanced by 6.45% to $2.1 billion in 2023, then increased by 15.76% to $2.5 billion in 2024, then grew by 9.46% to $2.7 billion in 2025, then fell by 4.77% to $2.6 billion in 2026.
  • The last three Gross Profit figures came in at $2.6 billion (Q1 2026), $2.7 billion (Q4 2025), and $2.7 billion (Q3 2025), per Business Quant data.